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Abstract 
Spinal muscular atrophy (SMA), a leading genetic cause of infant death, is a 
neurodegenerative disease characterised by the selective loss of particular groups of motor 
neurones in the anterior horn of the spinal cord with concomitant muscle weakness.  To date, 
no effective treatment is available, however, there are ongoing clinical trials are in place 
which promise much for the future. However, there remains an ongoing problem in trying to 
link a single gene loss to motor neurone degeneration. Fortunately, given successful disease 
models that have been established and intensive studies on SMN functions in the past ten 
years, we are fast approaching the stage of identifying the underlying mechanisms of SMA 
pathogenesis Here we discuss potential disease modifying factors on motor neurone 
vulnerability, in the belief that these factors give insight into the pathological mechanisms of 
SMA and therefore possible therapeutic targets. 
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Highlights: 
x Factors that influence vulnerability of motor neurons in SMA. 
x SMA disease modification. 
x Impact of surrounding cells on neuronal death. 
x Precise molecular defects in SMA; mRNA splicing and miRNA interactions. 
x Cytoskeletal stability and axonal transport effects. 
 
 
1. Introduction 
Spinal muscular atrophy (SMA) is an autosomal-recessive neurodegenerative disorder, 
caused by homozygous mutations in survival of motor neurone 1 (SMN1). It is characterised 
by the loss of a large number of lower motor neurones and muscle denervation. In general, 
there are four different types of SMA categorised according to the age of onset and level of 
motor function achieved [1]. Type 1 (Werdig Hoffman disease), the most severe type is also 
the most common genetic cause of infant mortality. Type 2 has a delayed onset around 0.5 
-1.5 years of age but still usually leads to death before adulthood. Patients with type 3 or type 
4 diseases typically can live a normal life with little assistance. The molecular basis for 
disease severity is associated with both the quality and quantity of SMN protein. In man, a 
unique gene called SMN2, which is a duplication of SMN1 and can be present in multiple 
copies. SMN2, has a near identical sequence but a crucial C to T substitution in exon 7 
frequently results in exclusion of this exon and an unstable transcript, thus causing a low 
yield of full-length protein product (Figure 1) [2, 3]. Also, some mutations in SMN1 do not 
cause complete loss of its function [4]. As a result, the disease severity is determined by both 
the preserved function of mutated SMN1 and the number of copies of SMN2 found in the 
patient genome.  
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Figure1. C to T conversion in SMN2 exon 7 results in a large part of protein products lacking 
exon7. This exon contains a domain important for self-association. Without oligomerisation, 
free-SMN undergoes degradation rapidly, further reducing the total SMN levels. 
 
The SMN1 mutation primarily affects lower motor neurones, the resulting motor neurone loss 
causing paralysis and early death due to respiratory failure. However, the reason why loss of 
a ubiquitously expressed protein causes motor neurones to be particularly more vulnerable 
than other cell types is an intriguing subject.  
Fortunately, given the studies on SMN function and a number of disease models established 
in the past ten years, we are beginning to understand what factors cause motor neurones to 
more prominently succumb to disease. These factors can be categorised into three major 
groups depending on external and internal effects on diseased motor neurones: First, it is 
known that as with other neurodegenerative diseases, other cell types contacting with the 
primary affected target cell also play a role in modulating disease severity: Motor neurones 
are surrounded by, and interact with, glia, such that faulty communication between these cells 
may exaggerate motor neurone pathology ± so-called non-cell autonomous effects. Second, 
SMN is a multifunctional protein involved in a number of processes including RNA 
maturation and transportation in axons. The low quality or quantity of SMN protein may 
dysregulate genes which are crucial for motor neurone development and survival, but less 
crucial for other cell types. Thirdly, there may be motor neurone-specific disease modifiers of 
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SMN effects or gene production. Here, we review factors that have either been demonstrated 
to, or have the potential to, influence motor neurone vulnerability.   
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2. Non cell-autonomous effects on motor neurone vulnerability 
Since the identification of the SMN gene and its role in SMA [2], multiple efforts have been 
made to understand how SMN restoration or deprivation in the motor neurone affects the 
disease phenotype. It has been shown that specifically elevating SMN in the motor neurones 
of SMA mice profoundly improves many morphological and physiological defects associated 
with motor neurones such as neuromuscular junction, (NMJ), breakdown, abnormal synaptic 
transmission, motor function, and motor neurone viability. However, there is still room for 
further functional improvement [5-7]. In addition, specific SMN deprivation in mouse motor 
neurones or delaying the induction of smn expression in fish does not necessarily generate 
manifestations of disease [8], thereby implying some other factor(s) or cell type(s) play a part 
in motor neurone vulnerability.  
To produce a movement, spinal motor neurones propagate the signal generated from the 
sensory neurone and inter-neurone, and then coordinate the signal to muscle fibres. Their 
normal function is highly regulated by neuroglia cells. In other words, the communication 
between all of these cell types is essential not only for effective motor movement but also for 
cell survival. In SMA, cells communicating with motor neurones are also under the stress of 
SMN malfunction, and as a result, they may contribute to motor neurone vulnerability. How 
these contacting cells respond to SMN malfunction and whether they negatively regulate 
motor neurone health will be considered in turn.   
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2.1. The role of muscle 
The bi-directional nature of communication at the NMJ has long been shown to play an 
essential role in the function of both the axon terminal and innervated muscle [9-12]. Cultures 
of neonatal chicken spinal neurones treated with muscle extracts from SMA patients show 
inhibition of neurite outgrowth [13]. Because of the accessibility and apparent malfunction of 
SMA muscle, many experiments have been carried out to determine whether muscle could be 
an effective therapeutic target or if there might be a retrograde effect from the muscle to the 
motor neurone compartment. 
Thus, selective knockdown of SMN levels in mouse skeletal muscle recapitulates the atrophic 
muscle fibres seen in SMA whilst motor neurone number and NMJ are spared [14]. Similarly, 
increased expression of SMN specifically in mature muscle (driven by the promoter of 
human skeletal actin, HSA, which is active only in mature myofibres) shows no benefit in 
nerve or muscle preservation, and little extension in lifespan in the SMN2 mouse model 
(smn-/-; SMN2+/+) [15]. A further investigation used MyoD (myogenic differentiation), whose 
expression begins at embryonic stage, to drive the expression of SMN in muscle in SMNǻ
mice (smn-/-; SMN2+/+; 601ǻ+/+). While this resulted in slightly increased survival and fully 
rescued muscle size, it again did not restore the motor neurone number, NMJ pathology, or 
motor behaviours such as the righting reflex [7].   
A further study demonstrated that whilst muscle could grow and function normally even 
when SMN is reduced to the disease level, and again no rescue was seen using an alternative 
promoter, (Myf5), to drive the muscle SMN expression in SMAǻ7 mice [16]. This result 
combined with previous work suggests the muscle weakness seen in SMA is a secondary 
change to the motor neurone pathology and there is minimal retrograde impact of defective 
SMN protein levels in muscle to motor neurones. 
2.2. Is a sensory neurone defect involved in inducing motor neurone pathology? 
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The significance of communication between sensory and motor neurones has been widely 
demonstrated. For example, NMJ formation is greatly facilitated by the presence of dorsal 
root ganglion neurones (DRG) in a co-culture system [17, 18]. Evidence for an impaired 
sensory system, including myelination loss and ganglion cell degeneration [19, 20], and 
absence of the refractory reaction following muscle spindle stimulation (H-reflex) are 
reported in some severe SMA cases [21]. Correspondingly, in mouse models of SMA, 
deafferentation from sensory inputs onto motor neurone results in lower input from 
presynaptic activity, which can account for the impaired motor activity of SMA [22-25]. In 
addition, SMN deprivation causes overlapping defects in both motor and sensory neurones, 
including reduced axonal hnRNP-R mRNA and growth cone size [26].  
 
These studies raise the question whether any abnormal communication onto the motor 
neurone might aggravate motor neurone pathology. This hypothesis received some initial 
support from an SMA Drosophila model, which has an obligate requirement for SMN in 
cholinergic neurones, proprioceptive neurones and partial interneurones but not in motor 
neurones, for recovering motor behaviours [27], suggesting that normal sensory or other 
inputs play an important role in regulating motor neurone impairment. 
However, there is concern that Drosophila has a nervous system that is not representative of 
higher organisms. For example, the neurotransmitters acetyl choline and glutamate are 
proprioceptive and motor in function in Drosophila respectively, but have converse functions 
in vertebrates. Thus, whether the role of SMN in Drosophila proprioceptive neurones is 
equivalent to that in vertebrate animals needs further investigation. 
 
Other SMN models have failed to support a role for sensory neurones in motor neurone 
degeneration.  VGlut1 puncta on motor neurones are the contact point where motor 
neurones receive input from sensory afferents, and are reduced in number in SMA mouse 
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models [6, 7, 25]. Boosting SMN protein in motor neurones is sufficient to fully rescue 
VGlut1 puncta number in SMA mouse models, suggesting motor-sensory deassociation may 
be secondary to motor neurone pathology [6, 7, 28]. Furthermore, motor neurone viability is 
independent of the motor-sensory communication when motor neurones are co-cultured with 
SMA sensory neurones derived from induced pluripotent stem cells (iPSCs) [29].  
The interaction of sensory and other neuronal cells with the motor neurone requires further 
investigation as a number of issues remain unresolved. For example, whether specific 
expression of SMN in other neuronal cells in a mammalian model affects motor neurone 
phenotype is yet to be investigated. 
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2.3. Glial cells 
There is a growing body of evidence implicating non-neuronal cells (glia) in various 
neurodegenerative diseases. There are various types of glia (principally astrocytes, 
oligodendrocytes and microglia) which have varied roles including the regulation of 
homeostasis, myelination and immune response [30]. 
Various astrocytic defects, including shorter process length and increased GFAP protein 
expression have been reported in pre-symptomatic SMAǻ7 mice [31]. Furthermore, both 
SMA iPSC-derived and primary astrocytes reveal abnormal Ca2+ homeostasis, an important 
molecule affecting cytosis [32, 33]. A study using mixed and matched co-cultures of motor 
neurones and astrocyte from wild type and SMA strains shows the importance of astrocyte in 
synapse formation and electrophysiological properties of motor neurones [33]. This is further 
verified in an in vivo study which demonstrated  a remarkable improvement in motor 
functions, NMJ occupancy ratio and life span when SMN is specifically restored in SMN 
astrocytes [33]. However, the functions of SMN in astrocytes did not include the mitigation 
of motor neurone death in both studies [33, 34]. 
In a study of Schwann cells (the myelinating glial cell of lower motor neurones in the 
perhiphery) in SMN2 and Taiwanese SMA mouse models, there was defective secretion of 
myelination and laminin proteins [35]. The former is required for effective motor axon 
transmission. Interestingly, this defect was not demonstrated in the corticospinal tract, 
indicating the peripheral nervous system is more sensitive to a myelination defect. Laminin is 
a known factor exerting a strong influence on neurite growth and motor neurone viability in 
vitro [36]. Moreover, laminin deficiency is a possible cause of motor axon shortening due to 
inhibition of local axonal translation [37]. 
. 
Although there has been no systematic study made on SMA microglia, there is in vivo 
evidence showing that microglia cells are also increased in number and activity in the spinal 
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cord of SMAǻ7 mice, suggesting the involvement of microglia in regulating motor neurone 
function by stripping synaptic input [25]. 
Although there is no direct link between motor neurone death and SMN malfunction in any 
kind of glial cells, a conclusion that can be drawn is that the interplays between motor 
neurone and glial cells may largely contribute to the clinical manifestations, suggesting SMA 
is a multi-system disorder. However, more evidence will be required to fully understand their 
roles. For example, It is known that ALS can be recapitulated by overexpressing mutant Sod1 
in astrocytes [38]. As such, it would be interesting to see how selective SMN reduction in 
glial cells could affect motor neurones.  
 
3. Autonomous motor neurone vulnerability 
SMA has long been considered as an autonomous motor neurone disease as there is 
considerable motor neurone loss whereas other cell types are relatively spared. The exact 
function of SMN, specifically in motor neurones as opposed to other cell types is unresolved. 
Such functional characterisation of the pathways that are affected by SMN would contribute 
considerably to our understanding of SMN pathogenesis (Table 1).  
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Modifying 
factor 
 
Modulating 
mechanism 
Model Ref. 
Stasimon Unknown Drosophila 
Zebrafish 
[39] 
Chondrolectin Neural 
development 
Zebrafish [40] 
SMN2 Exon 7 
inclusion 
Mouse [41] 
hnRNP-R mRNA 
transportation 
Zebrafish unpublished 
HuD Neural 
development 
mRNA 
transportation 
Cultured cell 
 
[42] 
IMP1 (ZBP1) mRNA 
transportation 
Cultured cell [43] 
CPG15 
(NEURITIN) 
NMJ 
maturation 
Zebrafish [44] 
PLS3 Actin dynamic Mouse 
Human 
 
[45, 46] 
Htra2-ȕ1 Exon 7 
inclusion 
Human [47] 
ROCK Actin dynamic Cultured cell 
Mouse 
[48, 49] 
PTEN Excitotoxcity Cultured cell 
Mouse 
[50, 51] 
 
NMDA Exon 7 
inclusion 
Mouse [52] 
ȕ-catenin Protein 
metabolism 
Zebrafish 
Mouse 
[53] 
UBA1 Protein 
metabolism 
Zebrafish 
Mouse 
[53, 54] 
UPR genes ER stress Cultured cell 
Mouse 
[55] 
IGF-1 SMN 
expression 
Mouse [56] 
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Table1. Known factors that modulate SMA severity 
 
CNTF NMJ formation Mouse [57] 
CT-1 NMJ formation Mouse [58] 
Bcl-XL Anti-apoptosis Mouse [59] 
miR-183 mToR pathway Cultured cell 
Mouse 
[60] 
miR-431 Chold 
regulation 
Cultured cell [61] 
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In addition to the direct effects of SMN, other modifying factors have functions that are 
independent of SMN functions but may be relevant to motor neurone diseases.  
Finally, it is apparent that motor neurones are not uniformly susceptible to SMA.  
Elucidation of the factors which render different populations of motor neurone vulnerable and 
resistant to SMA usefully contributes to our understanding of disease pathogenesis.  
In this section, we will focus on SMN-dependent functions. SMN is known to be an RNP 
assembly protein involved in the formation of snRNP and mRNP indicating potential roles in 
both RNA splicing and transportation. One can expect SMN loss would impair RNA splicing 
and transportation [62-65]. 
 
3.1. RNA splicing defect 
SMN has a key role in the assembly of small nuclear ribonucleoproteins (snRNPs), key 
components of the spliceosome machinery [66]. It is thus likely that disruption of RNA 
splicing is involved in SMA pathobiology [67]. Accordingly, studies have shown a direct 
correlation between the ability to assemble snRNP and SMA disease severity [68, 69]. 
Furthermore, restoring normal splicing function by delivering mature snRNP that do not 
contain SMN is sufficient to rescue SMA phenotypes in smn-depleted fish embryos [70].  
This raises the question:  Why does SMN loss of function cause selective motor neurone 
vulnerability if it affects such a fundamental process that occurs in all cell types? In answer to 
this, early studies found tissue- and spliceosome-specific splicing defects [71] that stress the 
differential influence of two complementary spliceosome complexes: The major spliceosome 
is involved in excising the majority of introns,  whilst the minor spliceosome is responsible 
for splicing only a few hundred genes in the genome [72]. There is growing speculation that 
the minor spliceosome may have a more pronounced role in neuronal homeostasis [73]. 
Minor spliceosome components are significantly reduced in the spinal cord of late-stage SMA 
mice whilst the major pathway remains normal [68, 71]. This raises the possibility that cell 
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populations expressing a greater proportion of genes that preferentially use this minor 
splicing pathway are more selectively affected, thereby contributing to selective motor 
neurone vulnerability. In support of the importance of the minor spliceosome to motor 
neurones, we, and others have found significant reductions of minor spliceosome components 
in amyotrophic lateral sclerosis [74, 75].  
Further support of this observation is the demonstration of mis-splicing of a number of minor 
spliceosome introns from a number of genes. For example, aberrant splicing of a minor 
spliceosome intron has been described in Stasimon (Stas) both in a Drosophila model of 
SMA and a dorsal root ganglion neurones of SMAǻ7 mice [39]. Stasimon is a 
transmembrane protein that appears to be essential for normal motor function. Co-injection of 
a Stas mRNA and smn morpholino is capable of rescuing the axonal growth defect seen in 
SMN-deficient Zebrafish, suggestive of its modifying role in the disease [39]. 
 
Whilst there is significant evidence that the minor spliceosomal pathway is affected in SMA, 
it is still expected that the major pathway will also be disrupted owing to the crucial role of 
SMN in snRNP biogenesis [67]. AQ H[RQ DUUD\ DQDO\VLV RI ODWH VWDJH 601ǻ PLFH VSLQDO
cord showed widespread splicing errors affecting both the major and minor spliceosome 
pathways but only in late stage disease[76]. For example, the gene Chodl, which encodes 
Chondrolectin, was identified as mis-spliced in this study. Chodl is normally spliced via the 
major pathway, is expressed at a high level in motor neurones and appears to be necessary for 
axonogenesis in zebrafish [77, 78]. A further study showed that its overexpression was able to 
partially rescue the neurite number and length in an smn-depleted NSC-34 cell line, and 
axonal growth in SMA fish [40]. However, the alternative splicing event seen in the mouse 
homologous gene does not occur in humans, so the precise relevance of this to human disease 
is yet to be determined [79]. 
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Cell-type specific RNA-seq analysis has identified several genes whose splicing is selectively 
disrupted in motor neurones, but not other neuronal populations, in spinal cord at a very early 
disease stage in SMAǻ7 mice (before post-natal day 1). Of these incorrectly spliced genes, 
agrn (agrin) is of particular interest [80]. Agrn is a stimulator of acetyl choline receptor 
(AChR) clustering, and as such is responsible for NMJ maturation [81]. Gene splicing of 
Gria4, which encodes the AMPA-type glutamate receptor 4, generates two splice isoforms, 
NQRZQDVµIOLS¶DQGµIORS¶. Receptors of the latter form desensitise more slowly. The ratio of 
flip to flop receptors is increased in motor neurone of SMAǻ7 mice [80], potentially 
explaining altered electrophysiological properties in SMA motor neurones [8, 22].  
Similarly, by transcriptome microarray analysis, a more recent study using smn knockdown 
zebrafish first identified dysregulation of neurexin2a (nrxn2a) in both its overall expression 
quantity and isoform ratio, and then validated these findings in motor neurone of SMN2 mice 
[82]. This gene acts at the pre-synaptic terminal regulating exocytosis and pre- and 
postsynaptic adhesion [83]. Experimental knockout of nrxn2a in mice has revealed various 
NMJ defects similar to those seen in motor neurone diseases [84, 85]. In keeping with its 
influence on motor axon terminal, knockdown of nrxn2a in wild type fish and raising the 
nrxn2a mRNA levels in a smn-deficient fish showed detrimental and beneficial effects on 
motor axon growth respectively [82]. However, nrxn2a was dysregulated both quantitatively 
and qualitatively, as such it remains to be shown which results in the motor neurone defect or 
a combination of both [82].  
In addition to SMN-deficiency mediated mRNA splicing disruption, it has also been 
suggested that the level of SMN2 exon 7 inclusion efficiency by the splicing machinery plays 
a fundamental role in motor neurone vulnerability: It is possible that SMN2 exon 7 inclusion 
is particularly low in some spinal motor neurones [41, 86] compared to other cell types.  
Whilst aberrant splicing may occur in SMA, it may be contributory but not be centrally 
causative to the pathology. For example, SMA-like phenotypes cannot be induced by 
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disturbing snRNP assembly or function [87-89]. Further, Baumer et al. found that splicing 
errors are only present on a large scale late in the disease [76]. This would suggest that other 
SMN functions are relevant to selective vulnerability at earlier stages of disease. 
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3.2. Axonal RNA transport defect 
Within the cell, SMN protein is not restricted to the nucleus where the snRNP assembly 
mainly takes place, as a small proportion of SMN is found in the axon in granular form 
[90-94]. These axonal SMN granules are free of Sm ribonucleoproteins  which are core 
components of the snRNP assembly of the spliceosome [91]. Furthermore, truncated SMN 
that lacks the functional domain necessary for snRNP assembly is able to partially rescue the 
disruption of axon pathfinding in SMA fish [92]. These data, combined with the evidence of 
prominent axon degeneration and/or an outgrowth defect seen in various SMA models, is 
suggestive of a direct role of SMN in SMA pathology occurring at the distal part of motor 
neurone [95-99].  
What does SMN do in the motor axon? It is possible that the RNA-binding feature of SMN 
and its associated molecules (many of them are RNA-binding proteins) allow them to 
transport RNA in cells beyond the snRNP biogenesis machinery [100, 101].  SMN 
co-localises with hnRNP-R in mouse motor neurones [102] and is associated with both 
hnRNP-5DQGȕ-actin mRNA in the motor axon and growth cone, and hence may affect local 
SURWHLQ V\QWKHVLV RI ȕ-actin [103, 104]. hnRNP-R is a member of hnRNP family and is 
involved in the various RNA regulatory functions including transport, splicing and 
metabolism. Knockdown of hnRNP-R has been shown to induce pronounced SMA-like 
phenotypes in zebrafish whereas other neuronal cells are less affected, similar to the 
phenotypes observed in smn morphant [104, 105]. Actin also plays an important role in axon 
structure and function [106-108].  However, whether and how actin-deficiency in a distal 
part contributes to axonopathy in SMA remains unclear [109].  
In a further study of the axon, SMN was found to co-localise with Hu-antigen D (HuD) 
protein and cpg15 (candidate plasticity-related gene 15, also known as neuritin) mRNA. [44]. 
HuD is a further RNA-binding protein with a pivotal role in neuronal cells that has been 
implicated in a wide range of activities including development, maintenance, and plasticity 
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[110]. This protein can act on the expression of a wide variety of mRNA species by binding 
to their 3¶UTR [111].  This mechanism is regulated by methylation via CARM1 [112]. It 
appears that the SMN protein can increase CARM1 translation causing an increase in HuD 
methylation. As such, SMN loss reduces the affinity of HuD for its target RNA which is 
likely to contribute to the SMA axonopathy. This defect can be partially rescued by HuD 
overexpression [42, 43, 113].  
 
cpg15 mRNA, which colocalises with SMN protein in the growth cone, appears to be 
involved in synaptic maturation in both sensory and motor neurones [114, 115]. cpg15 
overexpression in smn-deficient zebrafish partially rescued motor axon pathology [44]. 
However, although cpg15 mRNA is shown to be translated in the growth cone, its levels are 
not only decreased in neurites but also in the cell body upon SMN reduction. Therefore, 
whether cpg15 has a specific or more general impact on the motor axon remains unclear. 
Similarly, another protein, insulin-like growth factor mRNA-binding protein 1 (IMP1) ( also 
known as zipcode-binding protein 1 or ZBP1), has also been found to colocalise with SMN in 
axons [116]. This protein has some mRNA targets in common with HuD including ȕ-actin 
and Gap43 (microtubule-associated protein tau and the growth-associated protein 43), of 
which Gap43 is of particular interest because of its versatile role in regulating axonal 
functions. More recently, an in vitro study showed decreased levels of Gap43 in SMA axons, 
which were restored by overexpressing either HuD or IMP1, which also rescued the short 
axon phenotype [43]. 
Another SMN molecular partner involved in axonal transportation is coatomer subunit alpha 
Į-cop). Į-cop belongs to the coat protein complex I (COPI) that is responsible for 
Golgi-mediated transportation and also has the ability to bind a number of mRNAs [117]. 
SMN/Į-cop granules are found in neurites and this association is likely to have begun in the 
Golgi apparatus [118, 119]. Knockdown of Į-cop causes SMN accumulation in the Golgi 
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whereas over-expressing Į-cop increases neurite length in smn-depleted NSC34 cells [118, 
120]. These pieces of evidence further demonstrate there is a direct link between motor 
neurone vulnerability and axonal SMN.       
In line with the potential role of SMN in RNA transport, two studies used microarray analysis 
combined with microfluidic techniques to specifically isolate axonal RNA species. The 
studies identified about 400 RNA species potentially binding with axonal SMN. A further 
study found more than 1000 genes dysregulated in neurites of NSC-34 cells and smn-depleted 
primary mouse motor neurones [121-123]. Among these genes are a number involved in 
axonal outgrowth, synaptogenesis, neurogenesis and neurotransmitter release [121, 122].  
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4. Other modifiers 
In addition to SMN itself and its interacting partners, a number of genes have been identified 
that are able to ameliorate the SMA phenotype, as shown in table 1. These genes are 
putatively independent of SMN functions or appear to modify motor neurone vulnerability 
via less well defined pathways. In general, these modifiers are known to be essential for 
reducing neurodegenerative disease, with actions ranging from stabilising cytoskeleton, 
reducing excitotoxicity to regulating gene expression. 
 
4.1. Cytoskeleton stability 
Analysis of clinically discordant family members that carry homozygous deletions of SMN1 
and identical SMN2 copy number enable investigation of these modifiers. Following this 
approach, the expression of the F-actin bundling protein gene, Plastin 3 (PLS3), is 
significantly higher in unaffected females from six discordant families suffering with mild 
type of SMA (type II or III) [45]. However, further investigations demonstrated that 
overexpression of Pls3 in relatively severe SMA mouse modelV 7DLZDQHVH DQG 60$ǻ 
only shows marginal or no improvement [46, 124].Conversely, a more recent study 
demonstrates its strong beneficial effects on Taiwanese SMA mice when SMN protein 
quantity is slightly boosted [125]. These suggest PLS3 may serve as a protector when SMN 
protein is above a certain threshold level, or further factors are involved [126]. Along with the 
same PLS3 study, CORONIN 1C or CORO1C, another F-actin binding protein was also 
identified as a disease modulator through in vitro protein-protein interaction assays [125]. 
CORO1C displays a comparable beneficial result to that of overexpressing PLS3 in 
SMN-deficient zebrafish [125]. The mechanism underlying the rescue effect of both PLS3 
and CORO1C might involve an increase in the stability of the cytoskeleton and(or) restoring 
the endocytosis defect seen in SMN-deficient cells [125].  .  
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In addition to the role of SMN as an RNA carrier in the axon, another putative SMN function 
is the direct regulation of other protein activity in the axon. For example, SMN is able to bind 
non-phosphorylated profilin 2a protein, which is one of the substrates of rho-associated 
protein kinase (ROCK), an important regulator of actin dynamics [48, 127]. As a result of low 
SMN, it may upset the substrate balance for ROCK and in turn impairing actin dynamics. 
Inhibition of ROCK ameliorates the SMA-like phenotype both in cell culture and animal 
models [49], but knockout of one or both profilin 2a alleles does not cause any amelioration 
in a SMA mouse model [128]. As such, the exact mechanism of this effect remains to be 
explained.  
In addition to the impairment of actin dynamics, microtubule destruction has also been 
proposed to be a pathophysiological feature of both SMA and amyotrophic lateral sclerosis 
(ALS) [129, 130]. A regulator of microtubule dynamics, Stathmin, causes depolymerisation 
of microtubules, inhibiting axon outgrowth and organelle movement in the neuronal 
processes [131]. In a proteomic analysis of an SMA mouse model, stathmin was specifically 
upregulated in spinal cord but remained unchanged in the brain [130]. More importantly, the 
down regulation of stathmin in SMA-like motor neurones significantly recovered defects in 
the axonal transport of organelles such as mitochondria [130], supporting the idea that 
cytoskeletal changes exacerbate disease progression.  
 
4.2. Micro-RNA dysregulation 
A growing body of evidence has pointed to a role of micro-RNA (miRNA) in axonal 
outgrowth probably by regulating local translation [132-134]. Disruption of miRNA 
biogenesis causes SMA-like phenotypes [135]. Upon SMN loss, miR-183, which is known to 
target inhibition of mTor translation [136], is up-regulated in rat, human and mouse cells 
[137].  Knockdown of miR-183 results in a significant improvement in axonal length in 
smn-deficient rat motor neurones.  This improvement is present but small when the effect is 
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studied in vitro with the inhibition of miR-183 expression in CNS neurones of SMAǻ7 mice 
[60]. 
The upregulation of miR-431 has been observed in smn-knockdown  primary mouse motor 
neurones and occurs in a motor neurone-specific manner [61]. One of miR-431 targets is the 
aforementioned Chodl. Manipulation of miR-431 expression is able to increase and decrease 
neurite length under smn-depleted and normal conditions respectively [61].    
 
4.3. PTEN pathway 
Downregulation of phosphatase and tensin homolog (PTEN) is well known to have 
cytoprotective properties via its action on mTOR signalling, a pathway known to be involved 
in many neurodegenerative diseases. PTEN inhibition has been demonstrated to benefit ALS 
as well as SMA both in vivo and in vitro [50, 51, 138-140], by decreasing GluR1 and GluR2 
expression and apparently thereby reducing AMPA-mediated excitotoxicity [139]. 
 
4.4. Endoplasmic reticulum (ER) stress 
Although the activation of the unfolded protein response (UPR) under conditions of ER stress 
has been linked to many neurodegenerative disorders owing to its relationship with 
pathological protein aggregation [141]. iPSC-derived motor neurones from SMA patients 
have recently been shown to have higher ER stress activity compared to other induced spinal 
cord neurones and glia cells [55]. In SMAǻ7 mice, either knocking down UPR-related genes 
in vitro or treatment with an ER-stress inhibitor generates improvements in many aspects of 
the disease process including innervation, survival, and lifespan. However, the increase in ER 
stress activity seems to be a post-symptomatic event and therefore probably be a general 
response to the pathogenic mechanism [55].   
 
4.5. Increase of functional SMN 
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Because patients with SMA harbour an imperfect SMN1 gene, raising functional SMN 
protein levels has long been a tempting therapeutic strategy [142]. In general, this can be 
achieved by delivering synthetic DNA-like molecules to correct the splicing pattern 
[143-156], or small chemical compounds to alter the gene structure by inhibiting histone 
deacetylase [157-167]. To this end, several drugs, such as Nusinersen (Ionis/Biogen) , 
AVXS-101 (AveXis) and RG7916 (Rosche), have been developed and have been achieving 
some success in clinical trials . 
To compensate the weak association of SMN2 exon7 with splicing factors, upregulation of 
relevant splicing factors seems to be effective. An early attempt to identify a disease 
modifying gene in nine discordant families with variable SMA phenotypes found that there 
was an inverse correlation between the protein levels of an exon splicing enhancer, Htra2-ȕ1, 
and disease severity [47, 168]. This observation raises the possibility that all the elements 
subsequently identified to be involved in exon 7 inclusion are capable of modulating SMA 
[169-175].  
A further strategy to find potential modulators of SMN protein and/or expression levels is to 
identify a common pathway among several drugs that are frequently used to treat SMA. Thus, 
Stat5 (signal transducers and activators of transcription 5) was identified as a trans-element 
that regulated SMN expression: The amelioration of axon growth in SMA-like motor 
neurones was observed when transfecting with a continuously activated mutant of Stat5 
[176].  
In addition, SMN2 expression is raised upon the activation of the NMDA receptor achieved 
by exercise [177]. The increased level of SMN2 expression is most probably due to elevating 
the NMDA receptor-mediated PI3K/AKT/CREB cascade downstream activity [52, 177-179]. 
Taken together, it is possible that these factors are differentially regulated in motor neurones 
and other cell types as a weaker inclusion of SMN2 exon7 in motor neurone was reported [41, 
86]. Therefore, these factors might play an important role and may underlie selective motor 
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neurone vulnerability. Insulin/IGF-1 (Insulin-like growth factor 1) signalling has long been 
implicated in modulating neurodegenerative diseases [180]. In this regard, studies show 
increasing IGF-1 levels in SMA mice can have many phenotypic benefits including increased 
muscle size, motor function, lifespan, NMJ innervation and motor neurone number [56, 181]. 
Interestingly, although the mechanistic basis is unclear, both full-length SMN transcript and 
its protein product are considerably increased by this intervention [56]. However, the 
improvement in function becomes insignificant when delivering IGF-1 into a mild SMA 
mouse model, suggesting IGF-1 may only have a basic improvement that is only detectable 
when SMN protein is severely reduced. [182]. 
 
4.6. Neurotrophin, growth factor and anti-apoptosis 
Like IGF-1, other factors known to have positive effect on cell health and survivability have 
been shown to modify disease severity to different degrees. Ciliary neurotrophic factor 
(CNTF) and cardiotrophin-1 (CT-1), two neurotrophins commonly used to prolong motor 
neurone survival in vitro, are shown to be able to mitigate denervation in SMA mice [57, 58]. 
Over-expressing anti-apoptotic factor, Bcl-XL, can significantly ameliorate some SMA 
phenotypes, such as lifespan, motor functions and motor neurone number, in a mild SMA 
mouse model, but fail to recapitulate this effect in a severe one [59]. Notably, these studies of 
survival-promoting and anti-apoptotic factors were performed on less severe or mild SMA 
models. Whether they are still able to exert a protective effect in the more severe disease 
condition and whether the effect is motor neurone specific are questionable. Alternatively, 
they could act as an enhancer combined with other treatments. 
 
4.7. Causative genes for other motor neurone diseases 
TKH EURDGHVW VHQVH RI WKH WHUP ³PRWRU neurone GLVHDVHV´ FDQ UHIHU WR any disease that is 
characterised by progressive motor neurone loss and muscle weakness. Although they may 
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not be necessarily caused by the same mechanisms [183-185], these diseases may partially 
share common pathways with SMA and thus provide a possible opportunity to understand it. 
Mutations of ubiquitin-like modifier enzyme 1 (UBA1) cause X-linked infantile spinal 
muscular atrophy (XL-SMA), another form of motor neurone disease [186]. The protein 
product of this gene has also been found to be decreased in SMA mice. Pharmacological 
inhibition of its activity and raising its levels can reproduce and mitigate SMA phenotypes in 
fish respectively [53, 54]. In addition, comprehensive amelioration is observed upon 
increasing UBA1 levels in SMN-deficient mouse [54]. With respect to selective vulnerability, 
reduction of UBA1 affects ubiquitin homeostasis and causes accumulation of ȕ-catenin in the 
spinal cord but not in other organs such as liver and heart [53]. Inhibition of ȕ-catenin was 
shown to rescue NMJ pathology in SMA mouse whereas liver and heart showed no 
improvement in gross pathology, suggesting that ȕ-catenin accumulation may be a key to 
selective motor neurone vulnerability [53]. 
Several other genes have been identified as causes of hereditary motor neuropathies (HMNs) 
[184]. Although the roles of these genes are not yet fully investigated, they may be highly 
relevant to our current understanding of the underlying mechanism by which not only SMA 
but also other neurodegenerative diseases develop. For example, bicaudal D homolog 2 
(BICD2) [187-189], dynactin 1 (DCTN1) [190], vesicle-trafficking protein (VAPB) [191], and 
cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) [192, 193] are identified as causative genes 
of some HMNs. Some are involved in cargo packaging and retrograde axonal transport [194], 
while mutations in some of heat shock protein family which may cause the dysregulation of 
protein metabolism also induce HMNs [195-197]. Hence, it would be interesting to 
investigate their roles with SMN, and whether these genes are differentially regulated, 
thereby leading to selective motor neurone vulnerability. 
 
4.8. The nature of motor neurone vulnerability 
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Finally, clinical examination suggests that motor neurones are not affected equally during the 
disease course. Motor neurones are not entirely identical to each other, they develop, mature, 
locate, and innervate differentially. More specifically, the size [198, 199], NMJ maturation 
pathway [23, 200], motor column [22, 199], and motor pool [201-203] of motor neurones 
have been proposed to influence specific motor neurone vulnerability in SMA. As such, some 
modifying factors may be embedded and combined with the many other factors discussed 
above eventually leading to motor neurone vulnerability.   
More recently, two studies using SMA mouse models have shown that even motor neurones 
with very similar characteristics can display very distinct vulnerability [204, 205]. These 
studies suggest there are intrinsic molecular differences between vulnerable and less 
vulnerable motor neurones, some of which may make some motor neuron subgroups primed 
to the SMN loss. Whilst systematic investigation of relatively preserved versus vulnerable 
motor neurone groups has been performed in ALS [206, 207], an equivalent study has only 
recently been performed in a SMA mouse model [208]. This has revealed numerous 
encouraging candidate mechanisms, many of which have been previously identified as 
putative disease regulators in other research, such as programmed cell death, oxidative 
phosphorylation and ubiquitination. Novel pathways of potential interest that were identified 
include DNA repair, ribosome and rRNA binding [208]. However, it is still difficult to 
distinguish whether the changes are primary or secondary to the SMN loss.  
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5. Conclusion  
This review summarises the current knowledge of why some cells are more or less 
susceptible to SMA and describes some of the known factors that play a part in ameliorating 
disease severity. We believe that such investigations will not only shed light on SMA but also 
other motor neurone diseases such as ALS. For example, the protein products of disease 
causative genes for familial ALS such as TARDBP  and FUS  have been demonstrated to 
interact with SMN [209, 210]. In addition, SMN and SOD1 proteins interact within neurones 
and can potentially counteract functional deficits in each other [211, 212]. These suggest a 
shared pathway between these two most common motor neurone diseases.  
What makes spinal motor neurones particularly prone to the disease? The answer to this 
question relies on a more detailed functional analysis of SMN not only in the motor neurone 
but also the other interacting cell types, and to identify the specific features that are present in 
motor neurones. Novel insights into motor neurone vulnerability together with greater 
understanding of SMN function will move us closer to designing effective treatments for 
SMA patients and this process might become a study paradigm of selective vulnerability for 
other neurodegenerative diseases. 
 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not for profit sectors.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
References 
 
1. Lunn, M.R. and C.H. Wang, Spinal muscular atrophy. The Lancet, 2008. 371(9630): p. 
2120-2133. 
2. Lefebvre, S., et al., Identification and characterization of a spinal muscular 
atrophy-determining gene. Cell, 1995. 80(1): p. 155-165. 
3. Lefebvre, S., et al., Correlation between severity and SMN protein level in spinal 
muscular atrophy. Nature genetics, 1997. 16(3): p. 265-269. 
4. Burghes, A.H. and C.E. Beattie, Spinal muscular atrophy: why do low levels of 
survival motor neuron protein make motor neurons sick? Nature Reviews 
Neuroscience, 2009. 10(8): p. 597-609. 
5. Lee, A.J., et al., Limited phenotypic effects of selectively augmenting the SMN protein 
in the neurons of a mouse model of severe spinal muscular atrophy. PloS one, 2012. 
7(9): p. e46353. 
6. Gogliotti, R.G., et al., Motor neuron rescue in spinal muscular atrophy mice 
demonstrates that sensory-motor defects are a consequence, not a cause, of motor 
neuron dysfunction. The Journal of Neuroscience, 2012. 32(11): p. 3818-3829. 
7. Martinez, T.L., et al., Survival motor neuron protein in motor neurons determines 
synaptic integrity in spinal muscular atrophy. The Journal of Neuroscience, 2012. 
32(25): p. 8703-8715. 
8. Park, G.-H., et al., Reduced survival of motor neuron (SMN) protein in motor 
neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in 
model mice expressing the human centromeric (SMN2) gene. The Journal of 
Neuroscience, 2010. 30(36): p. 12005-12019. 
9. Rimer, M., et al., Ȗ-AChR/׫-AChR switch at agrin-induced postsynaptic-like 
apparatus in skeletal muscle. Molecular and Cellular Neuroscience, 1997. 9(4): p. 
254-263. 
10. Brenner, H., T. Lømo, and R. Williamson, Control of end-plate channel properties by 
neurotrophic effects and by muscle activity in rat. The Journal of physiology, 1987. 
388(1): p. 367-381. 
11. Thompson, W., Synapse elimination in neonatal rat muscle is sensitive to pattern of 
muscle use. Nature, 1983. 302(5909): p. 614-616. 
12. Marques, M.J., J.-A. Conchello, and J.W. Lichtman, From plaque to pretzel: fold 
formation and acetylcholine receptor loss at the developing neuromuscular junction. 
The Journal of Neuroscience, 2000. 20(10): p. 3663-3675. 
13. Henderson, C., et al., Extracts of muscle biopsies from patients with spinal muscular 
atrophies inhibit neurite outgrowth from spinal neurons. Neurology, 1987. 37(8): p. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
1361-1361. 
14. Cifuentes-Diaz, C., et al., Deletion of murine SMN exon 7 directed to skeletal muscle 
leads to severe muscular dystrophy. The Journal of cell biology, 2001. 152(5): p. 
1107-1114. 
15. Gavrilina, T.O., et al., Neuronal SMN expression corrects spinal muscular atrophy in 
severe SMA mice while muscle-specific SMN expression has no phenotypic effect. 
Human molecular genetics, 2008. 17(8): p. 1063-1075. 
16. Iyer, C.C., et al., Low levels of Survival Motor Neuron protein are sufficient for 
QRUPDO PXVFOH IXQFWLRQ LQ WKH 601ǻ PRXVH PRGHO RI 60$ Human molecular 
genetics, 2015: p. ddv332. 
17. Kobayashi, T., V. Askanas, and W.K. Engel, Human muscle cultured in monolayer and 
cocultured with fetal rat spinal cord: importance of dorsal root ganglia for achieving 
successful functional innervation. The Journal of neuroscience, 1987. 7(10): p. 
3131-3141. 
18. Anne-Sophie, A., C. Martine, and H. Christoph, A functional motor unit in the culture 
dish: co-culture of spinal cord explants and muscle cells. Journal of visualized 
experiments, 2012(62). 
19. Marshall, A. and L. Duchen, Sensory system involvement in infantile spinal muscular 
atrophy. Journal of the neurological sciences, 1975. 26(3): p. 349-359. 
20. Rudnik-Schöneborn, S., et al., Classical infantile spinal muscular atrophy with SMN 
deficiency causes sensory neuronopathy. Neurology, 2003. 60(6): p. 983-987. 
21. Renault, F., et al., [Electromyographic study of 50 cases of Werdnig-Hoffmann 
disease] . Revue d'electroencephalographie et de neurophysiologie clinique, 1983. 
13(3): p. 301-305. 
22. Mentis, G.Z., et al., Early functional impairment of sensory-motor connectivity in a 
mouse model of spinal muscular atrophy. Neuron, 2011. 69(3): p. 453-467. 
23. Murray, L.M., et al., Pre-symptomatic development of lower motor neuron 
connectivity in a mouse model of severe spinal muscular atrophy. Human molecular 
genetics, 2010. 19(3): p. 420-433. 
24. Mikesh, M., et al., Muscles in a mouse model of spinal muscular atrophy show 
profound defects in neuromuscular development even in the absence of failure in 
neuromuscular transmission or loss of motor neurons. Developmental biology, 2011. 
356(2): p. 432-444. 
25. Ling, K.K., et al., Synaptic defects in the spinal and neuromuscular circuitry in a 
mouse model of spinal muscular atrophy. PLoS One, 2010. 5(11): p. e15457. 
26. Jablonka, S., et al., Distinct and overlapping alterations in motor and sensory neurons 
in a mouse model of spinal muscular atrophy. Human molecular genetics, 2006. 15(3): 
p. 511-518. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
27. Imlach, W.L., et al., SMN Is Required for Sensory-Motor Circuit Function in< i>  
Drosophila</i> . Cell, 2012. 151(2): p. 427-439. 
28. Thirumalai, V., et al., Preservation of VGLUT1 synapses on ventral 
calbindin-immunoreactive interneurons and normal locomotor function in a mouse 
model of spinal muscular atrophy. Journal of neurophysiology, 2013. 109(3): p. 
702-710. 
29. Schwab, A.J. and A.D. Ebert, Sensory Neurons Do Not Induce Motor Neuron Loss in 
a Human Stem Cell Model of Spinal Muscular Atrophy. PloS one, 2014. 9(7): p. 
e103112. 
30. Maragakis, N.J. and J.D. Rothstein, Mechanisms of disease: astrocytes in 
neurodegenerative disease. Nature Clinical Practice Neurology, 2006. 2(12): p. 
679-689. 
31. McGivern, J.V., et al., Spinal muscular atrophy astrocytes exhibit abnormal calcium 
regulation and reduced growth factor production. Glia, 2013. 61(9): p. 1418-1428. 
32. Parpura, V. and R. Zorec, Gliotransmission: exocytotic release from astrocytes. Brain 
research reviews, 2010. 63(1): p. 83-92. 
33. Zhou, C., Z. Feng, and C.-P. Ko, Defects in Motoneuron±Astrocyte Interactions in 
Spinal Muscular Atrophy. The Journal of Neuroscience, 2016. 36(8): p. 2543-2553. 
34. Rindt, H., et al., Astrocytes influence the severity of spinal muscular atrophy. Human 
molecular genetics, 2015: p. ddv148. 
35. Hunter, G., et al., SMN-dependent intrinsic defects in Schwann cells in mouse models 
of spinal muscular atrophy. Human molecular genetics, 2013: p. ddt612. 
36. Dertinger, S.K., et al., Gradients of substrate-bound laminin orient axonal 
specification of neurons. Proceedings of the National Academy of Sciences, 2002. 
99(20): p. 12542-12547. 
37. Rathod, R., et al., /DPLQLQ LQGXFHG ORFDO D[RQDO WUDQVODWLRQ RI ȕ-actin mRNA is 
impaired in SMN-deficient motoneurons. Histochemistry and cell biology, 2012. 
138(5): p. 737-748. 
38. Nagai, M., et al., Astrocytes expressing ALS-linked mutated SOD1 release factors 
selectively toxic to motor neurons. Nature neuroscience, 2007. 10(5): p. 615-622. 
39. Lotti, F., et al., An SMN-dependent U12 splicing event essential for motor circuit 
function. Cell, 2012. 151(2): p. 440-454. 
40. Sleigh, J.N., et al., Chondrolectin affects cell survival and neuronal outgrowth in in 
vitro and in vivo models of spinal muscular atrophy. Human molecular genetics, 2014. 
23(4): p. 855-869. 
41. Ruggiu, M., et al., A role for SMN exon 7 splicing in the selective vulnerability of 
motor neurons in spinal muscular atrophy. Molecular and cellular biology, 2012. 
32(1): p. 126-138. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
42. Hubers, L., et al., HuD interacts with survival motor neuron protein and can rescue 
spinal muscular atrophy-like neuronal defects. Human molecular genetics, 2011. 
20(3): p. 553-579. 
43. Fallini, C., et al., Deficiency of the Survival of Motor Neuron Protein Impairs mRNA 
Localization and Local Translation in the Growth Cone of Motor Neurons. The 
Journal of Neuroscience, 2016. 36(13): p. 3811-3820. 
44. Akten, B., et al., Interaction of survival of motor neuron (SMN) and HuD proteins 
with mRNA cpg15 rescues motor neuron axonal deficits. Proceedings of the National 
Academy of Sciences, 2011. 108(25): p. 10337-10342. 
45. Oprea, G.E., et al., Plastin 3 is a protective modifier of autosomal recessive spinal 
muscular atrophy. Science, 2008. 320(5875): p. 524-527. 
46. Ackermann, B., et al., Plastin 3 ameliorates spinal muscular atrophy via delayed axon 
pruning and improves neuromuscular junction functionality. Human molecular 
genetics, 2013. 22(7): p. 1328-1347. 
47. Helmken, C., et al., Evidence for a modifying pathway in SMA discordant families: 
reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. 
Human genetics, 2003. 114(1): p. 11-21. 
48. Nölle, A., et al., The spinal muscular atrophy disease protein SMN is linked to the 
rho-kinase pathway via profilin. Human molecular genetics, 2011. 20(24): p. 
4865-4878. 
49. Bowerman, M., et al., Rho-kinase inactivation prolongs survival of an intermediate 
SMA mouse model. Human molecular genetics, 2010. 19(8): p. 1468-1478. 
50. Ning, K., et al., PTEN depletion rescues axonal growth defect and improves survival 
in SMN-deficient motor neurons. Human molecular genetics, 2010. 19(16): p. 
3159-3168. 
51. Little, D., et al., PTEN depletion decreases disease severity and modestly prolongs 
survival in a mouse model of spinal muscular atrophy. Molecular Therapy, 2015. 
23(2): p. 270-277. 
52. Biondi, O., et al., In vivo NMDA receptor activation accelerates motor unit 
maturation, protects spinal motor neurons, and enhances SMN2 gene expression in 
severe spinal muscular atrophy mice. The Journal of Neuroscience, 2010. 30(34): p. 
11288-11299. 
53. Wishart, T.M., et al., '\VUHJXODWLRQRIXELTXLWLQKRPHRVWDVLVDQGȕ-catenin signaling 
promote spinal muscular atrophy. The Journal of clinical investigation, 2014. 124(4): 
p. 0-0. 
54. Powis, R.A., et al., Systemic restoration of UBA1 ameliorates disease in spinal 
muscular atrophy. JCI Insight, 2016. 1(11). 
55. Ng, S.-Y., et al., Genome-wide RNA-Seq of Human Motor Neurons Implicates 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Selective ER Stress Activation in Spinal Muscular Atrophy. Cell stem cell, 2015. 
56. Tsai, L.-K., et al., Systemic administration of a recombinant AAV1 vector encoding 
IGF-1 improves disease manifestations in SMA mice. Molecular Therapy, 2014. 22(8): 
p. 1450-1459. 
57. Simon, C.M., et al., Ciliary neurotrophic factor-induced sprouting preserves motor 
function in a mouse model of mild spinal muscular atrophy. Human molecular 
genetics, 2010. 19(6): p. 973-986. 
58. Lesbordes, J.-C., et al., Therapeutic benefits of cardiotrophin-1 gene transfer in a 
mouse model of spinal muscular atrophy. Human Molecular Genetics, 2003. 12(11): p. 
1233-1239. 
59. Tsai, L.-K., et al., Restoring Bcl-x L levels benefits a mouse model of spinal muscular 
atrophy. Neurobiology of disease, 2008. 31(3): p. 361-367. 
60. Kye, M.J., et al., SMN regulates axonal local translation via miR-183/mTOR pathway. 
Human molecular genetics, 2014: p. ddu350. 
61. Wertz, M.H., et al., Cell type-specific miR-431 dysregulation in a motor neuron model 
of Spinal Muscular Atrophy. Human Molecular Genetics, 2016: p. ddw084. 
62. Li, D.K., et al. SMN control of RNP assembly: from post-transcriptional gene 
regulation to motor neuron disease. in Seminars in cell & developmental biology. 
2014. Elsevier. 
63. Wang, E.T., et al., Dysregulation of mRNA Localization and Translation in Genetic 
Disease. Journal of Neuroscience, 2016. 36(45): p. 11418-11426. 
64. Donlin-Asp, P.G., G.J. Bassell, and W. Rossoll, A role for the survival of motor 
neuron protein in mRNP assembly and transport. Current opinion in neurobiology, 
2016. 39: p. 53-61. 
65. So, B.R., et al., A U1 snRNP-specific assembly pathway reveals the SMN complex as 
a versatile hub for RNP exchange. Nature structural & molecular biology, 2016. 
66. Will, C.L. and R. Lührmann, Spliceosome structure and function. Cold Spring Harbor 
perspectives in biology, 2011. 3(7): p. a003707. 
67. Pellizzoni, L., J. Yong, and G. Dreyfuss, Essential role for the SMN complex in the 
specificity of snRNP assembly. Science, 2002. 298(5599): p. 1775-1779. 
68. Gabanella, F., et al., Ribonucleoprotein assembly defects correlate with spinal 
muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. 
PloS one, 2007. 2(9): p. e921. 
69. Workman, E., et al., A SMN missense mutation complements SMN2 restoring snRNPs 
and rescuing SMA mice. Human molecular genetics, 2009. 18(12): p. 2215-2229. 
70. Winkler, C., et al., Reduced U snRNP assembly causes motor axon degeneration in an 
animal model for spinal muscular atrophy. Genes & development, 2005. 19(19): p. 
2320-2330. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
71. Zhang, Z., et al., SMN deficiency causes tissue-specific perturbations in the repertoire 
of snRNAs and widespread defects in splicing. Cell, 2008. 133(4): p. 585-600. 
72. Levine, A. and R. Durbin, A computational scan for U12-dependent introns in the 
human genome sequence. Nucleic Acids Research, 2001. 29(19): p. 4006-4013. 
73. Onodera, O., et al., Minor splicing pathway is not minor any more: Implications for 
the pathogenesis of motor neuron diseases. Neuropathology, 2014. 34(1): p. 99-107. 
74. Highley, J.R., et al., Loss of nuclear TDPͲ43 in amyotrophic lateral sclerosis (ALS) 
causes altered expression of splicing machinery and widespread dysregulation of RNA 
splicing in motor neurones. Neuropathology and applied neurobiology, 2014. 40(6): p. 
670-685. 
75. Ishihara, T., et al., Decreased number of Gemini of coiled bodies and U12 snRNA 
level in amyotrophic lateral sclerosis. Human molecular genetics, 2013. 22(20): p. 
4136-4147. 
76. Bäumer, D., et al., Alternative splicing events are a late feature of pathology in a 
mouse model of spinal muscular atrophy. PLoS genetics, 2009. 5(12): p. e1000773. 
77. Zhong, Z., et al., Chondrolectin mediates growth cone interactions of motor axons 
with an intermediate target. The Journal of Neuroscience, 2012. 32(13): p. 
4426-4439. 
78. Enjin, A., et al., Identification of novel spinal cholinergic genetic subtypes disclose 
Chodl and Pitx2 as markers for fast motor neurons and partition cells. Journal of 
Comparative Neurology, 2010. 518(12): p. 2284-2304. 
79. Weng, L., et al., Molecular cloning and characterization of human chondrolectin, a 
novel type I transmembrane protein homologous to C-type lectins. Genomics, 2002. 
80(1): p. 62-70. 
80. Zhang, Z., et al., Dysregulation of synaptogenesis genes antecedes motor neuron 
pathology in spinal muscular atrophy. Proceedings of the National Academy of 
Sciences, 2013. 110(48): p. 19348-19353. 
81. Bezakova, G. and M.A. Ruegg, New insights into the roles of agrin. Nature Reviews 
Molecular Cell Biology, 2003. 4(4): p. 295-309. 
82. See, K., et al., SMN deficiency alters Nrxn2 expression and splicing in zebrafish and 
mouse models of spinal muscular atrophy. Human molecular genetics, 2014. 23(7): p. 
1754-1770. 
83. Lise, M. and A. El-Husseini, The neuroligin and neurexin families: from structure to 
function at the synapse. Cellular and Molecular Life Sciences CMLS, 2006. 63(16): p. 
1833-1849. 
84. Zhang, W., et al., ([WUDFHOOXODU GRPDLQV RI Į-neurexins participate in regulating 
synaptic transmission by selectively affecting N-and P/Q-type Ca2+ channels. The 
Journal of neuroscience, 2005. 25(17): p. 4330-4342. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
85. Missler, M., et al., Į-Neurexins couple Ca2&plus; channels to synaptic vesicle 
exocytosis. Nature, 2003. 423(6943): p. 939-948. 
86. Jodelka, F.M., et al., A feedback loop regulates splicing of the spinal muscular 
atrophy-modifying gene, SMN2. Human molecular genetics, 2010. 19(24): p. 
4906-4917. 
87. Tucker, K.E., et al., Residual Cajal bodies in coilin knockout mice fail to recruit Sm 
snRNPs and SMN, the spinal muscular atrophy gene product. The Journal of cell 
biology, 2001. 154(2): p. 293-308. 
88. Hebert, M.D., et al., Coilin forms the bridge between Cajal bodies and SMN, the 
spinal muscular atrophy protein. Genes & development, 2001. 15(20): p. 2720-2729. 
89. McWhorter, M.L., et al., The SMN binding protein Gemin2 is not involved in motor 
axon outgrowth. Developmental neurobiology, 2008. 68(2): p. 182-194. 
90. Zhang, H.L., et al., Active transport of the survival motor neuron protein and the role 
of exon-7 in cytoplasmic localization. The Journal of neuroscience, 2003. 23(16): p. 
6627-6637. 
91. Zhang, H., et al., Multiprotein complexes of the survival of motor neuron protein SMN 
with Gemins traffic to neuronal processes and growth cones of motor neurons. The 
Journal of neuroscience, 2006. 26(33): p. 8622-8632. 
92. Zhang, H., et al., QNQKE targeting motif for the SMNͲGemin multiprotein complexin 
neurons. Journal of neuroscience research, 2007. 85(12): p. 2657-2667. 
93. Fallini, C., et al., The survival of motor neuron (SMN) protein interacts with the 
mRNA-binding protein HuD and regulates localization of poly (A) mRNA in primary 
motor neuron axons. The Journal of Neuroscience, 2011. 31(10): p. 3914-3925. 
94. Carrel, T.L., et al., Survival motor neuron function in motor axons is independent of 
functions required for small nuclear ribonucleoprotein biogenesis. The Journal of 
neuroscience, 2006. 26(43): p. 11014-11022. 
95. Liu, H., et al., Neurodevelopmental consequences of Smn depletion in a mouse model 
of spinal muscular atrophy. Journal of neuroscience research, 2010. 88(1): p. 111-122. 
96. McWhorter, M.L., et al., Knockdown of the survival motor neuron (Smn) protein in 
zebrafish causes defects in motor axon outgrowth and pathfinding. The Journal of cell 
biology, 2003. 162(5): p. 919-932. 
97. MartínezͲHernández, R., et al., Synaptic defects in type I spinal muscular atrophy in 
human development. The Journal of pathology, 2013. 229(1): p. 49-61. 
98. McGovern, V.L., et al., Embryonic motor axon development in the severe SMA mouse. 
Human molecular genetics, 2008. 17(18): p. 2900-2909. 
99. Murray, L., K. Talbot, and T. Gillingwater, Review: neuromuscular synaptic 
vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal 
muscular atrophy. Neuropathology and applied neurobiology, 2010. 36(2): p. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
133-156. 
100. Bertrandy, S., et al., The RNA-binding properties of SMN: deletion analysis of the 
zebrafish orthologue defines domains conserved in evolution. Human molecular 
genetics, 1999. 8(5): p. 775-782. 
101. Fallini, C., G.J. Bassell, and W. Rossoll, Spinal muscular atrophy: The role of SMN in 
axonal mRNA regulation. Brain research, 2012. 1462: p. 81-92. 
102. Dombert, B., et al., Presynaptic Localization of Smn and hnRNP R in Axon Terminals 
of Embryonic and Postnatal Mouse Motoneurons. PloS one, 2014. 9(10): p. e110846. 
103. Rossoll, W., et al., Specific interaction of Smn, the spinal muscular atrophy 
determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in 
RNA processing in motor axons? Human molecular genetics, 2002. 11(1): p. 93-105. 
104. Rossoll, W., et al., Smn, the spinal muscular atrophy±determining gene product, 
PRGXODWHV D[RQ JURZWK DQG ORFDOL]DWLRQ RI ȕ-actin mRNA in growth cones of 
motoneurons. The Journal of cell biology, 2003. 163(4): p. 801-812. 
105. Glinka, M., et al., The heterogeneous nuclear ribonucleoprotein-R is necessary for 
D[RQDO ȕ-actin mRNA translocation in spinal motor neurons. Human molecular 
genetics, 2010. 19(10): p. 1951-1966. 
106. Bloom, O., et al., Colocalization of synapsin and actin during synaptic vesicle 
recycling. The Journal of cell biology, 2003. 161(4): p. 737-747. 
107. Doussau, F. and G.J. Augustine, The actin cytoskeleton and neurotransmitter release: 
an overview. Biochimie, 2000. 82(4): p. 353-363. 
108. Vogelaar, C.F., et al., Axonal mRNAs: characterisation and role in the growth and 
regeneration of dorsal root ganglion axons and growth cones. Molecular and Cellular 
Neuroscience, 2009. 42(2): p. 102-115. 
109. Cheever, T.R., E.A. Olson, and J.M. Ervasti, Axonal regeneration and neuronal 
function are preserved in motor neurons lacking ss-actin in vivo. PLoS One, 2011. 
6(3): p. e17768. 
110. DeschênesͲFurry, J., N. PerroneͲBizzozero, and B.J. Jasmin, The RNAͲbinding protein 
HuD: a regulator of neuronal differentiation, maintenance and plasticity. Bioessays, 
2006. 28(8): p. 822-833. 
111. Bronicki, L.M. and B.J. Jasmin, Emerging complexity of the HuD/ELAVl4 gene; 
implications for neuronal development, function, and dysfunction. Rna, 2013. 19(8): p. 
1019-1037. 
112. Fujiwara, T., et al., CARM1 regulates proliferation of PC12 cells by methylating HuD. 
Molecular and cellular biology, 2006. 26(6): p. 2273-2285. 
113. Sanchez, G., et al., A novel function for the survival motoneuron protein as a 
translational regulator. Human molecular genetics, 2013. 22(4): p. 668-684. 
114. Willis, D.E., et al., Extracellular stimuli specifically regulate localized levels of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
individual neuronal mRNAs. The Journal of cell biology, 2007. 178(6): p. 965-980. 
115. Fujino, T., et al., CPG15 regulates synapse stability in the developing and adult brain. 
Genes & development, 2011. 25(24): p. 2674-2685. 
116. Fallini, C., et al., Dynamics of survival of motor neuron (SMN) protein interaction 
with the mRNAͲbinding protein IMP1 facilitates its trafficking into motor neuron 
axons. Developmental neurobiology, 2014. 74(3): p. 319-332. 
117. Todd, A.G., et al., COPI transport complexes bind to specific RNAs in neuronal cells. 
Human molecular genetics, 2013. 22(4): p. 729-736. 
118. Ting, C.-H., et al., The spinal muscular atrophy disease protein SMN is linked to the 
Golgi network. PloS one, 2012. 7(12): p. e51826. 
119. Peter, C.J., et al., The COPI vesicle complex binds and moves with survival motor 
neuron within axons. Human molecular genetics, 2011. 20(9): p. 1701-1711. 
120. Custer, S.K., et al., Dilysine motifs in exon 2b of SMN protein mediate binding to the 
&23,YHVLFOHSURWHLQĮ-COP and neurite outgrowth in a cell culture model of spinal 
muscular atrophy. Human molecular genetics, 2013. 22(20): p. 4043-4052. 
121. Rage, F., et al., Genome-wide identification of mRNAs associated with the protein 
SMN whose depletion decreases their axonal localization. RNA, 2013. 19(12): p. 
1755-1766. 
122. Saal, L., et al., Subcellular transcriptome alterations in a cell culture model of spinal 
muscular atrophy point to widespread defects in axonal growth and presynaptic 
differentiation. RNA, 2014. 
123. Taylor, A.M., et al., A microfluidic culture platform for CNS axonal injury, 
regeneration and transport. Nature methods, 2005. 2(8): p. 599-605. 
124. McGovern, V.L., et al., Plastin 3 Expression Does Not Modify Spinal Muscular 
$WURSK\6HYHULW\LQWKH¨60$0RXVH PloS one, 2015. 10(7): p. e0132364. 
125. Hosseinibarkooie, S., et al., The Power of Human Protective Modifiers: PLS3 and 
CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue 
SMA Phenotype. The American Journal of Human Genetics, 2016. 99(3): p. 647-665. 
126. Bernal, S., et al., Plastin 3 expression in discordant spinal muscular atrophy (SMA) 
siblings. Neuromuscular Disorders, 2011. 21(6): p. 413-419. 
127. Sharma, A., et al., A role for complexes of survival of motor neurons (SMN) protein 
with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells. 
Experimental cell research, 2005. 309(1): p. 185-197. 
128. Bowerman, M., et al., SMN, profilin IIa and plastin 3: a link between the deregulation 
of actin dynamics and SMA pathogenesis. Molecular and Cellular Neuroscience, 2009. 
42(1): p. 66-74. 
129. Strey, C.W., et al., Dysregulation of stathmin, a microtubule-destabilizing protein, and 
up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
of familial amyotrophic lateral sclerosis. The American journal of pathology, 2004. 
165(5): p. 1701-1718. 
130. Wen, H.-L., et al., Stathmin, a microtubule-destabilizing protein, is dysregulated in 
spinal muscular atrophy. Human molecular genetics, 2010: p. ddq058. 
131. Jourdain, L., et al., Stathmin: a tubulin-sequestering protein which forms a ternary 
T2S complex with two tubulin molecules. Biochemistry, 1997. 36(36): p. 
10817-10821. 
132. Zhang, Y., et al., The microRNA-17±92 cluster enhances axonal outgrowth in 
embryonic cortical neurons. The Journal of Neuroscience, 2013. 33(16): p. 
6885-6894. 
133. Kar, A.N., et al., Intra-axonal synthesis of eukaryotic translation initiation factors 
regulates local protein synthesis and axon growth in rat sympathetic neurons. The 
Journal of Neuroscience, 2013. 33(17): p. 7165-7174. 
134. Zhu, H., et al., Skeletal muscle calpain acts through nitric oxide and neural miRNAs 
to regulate acetylcholine release in motor nerve terminals. The Journal of 
Neuroscience, 2013. 33(17): p. 7308-7324. 
135. Haramati, S., et al., miRNA malfunction causes spinal motor neuron disease. 
Proceedings of the National Academy of Sciences, 2010. 107(29): p. 13111-13116. 
136. Weeraratne, S.D., et al., Pleiotropic effects of miR-183~ 96~ 182 converge to regulate 
cell survival, proliferation and migration in medulloblastoma. Acta neuropathologica, 
2012. 123(4): p. 539-552. 
137. Liu-Yesucevitz, L., et al., Local RNA translation at the synapse and in disease. The 
Journal of Neuroscience, 2011. 31(45): p. 16086-16093. 
138. Kirby, J., et al., Phosphatase and tensin homologue/protein kinase B pathway linked 
to motor neuron survival in human superoxide dismutase 1-related amyotrophic 
lateral sclerosis. Brain, 2011. 134(2): p. 506-517. 
139. Yang, D., et al., PTEN regulates AMPA receptor-mediated cell viability in iPS-derived 
motor neurons. Cell death & disease, 2014. 5(2): p. e1096. 
140. Little, D., et al., PTEN Depletion Decreases Disease Severity and Modestly Prolongs 
Survival in a Mouse Model of Spinal Muscular Atrophy. Molecular Therapy, 2014. 
141. Saxena, S. and P. Caroni, Selective neuronal vulnerability in neurodegenerative 
diseases: from stressor thresholds to degeneration. Neuron, 2011. 71(1): p. 35-48. 
142. Garber, K., Big win possible for Ionis/Biogen antisense drug in muscular atrophy. 
2016, Nature Research. 
143. Porensky, P.N., et al., A single administration of morpholino antisense oligomer 
rescues spinal muscular atrophy in mouse. Human molecular genetics, 2012. 21(7): p. 
1625-1638. 
144. Passini, M.A., et al., Antisense oligonucleotides delivered to the mouse CNS 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
ameliorate symptoms of severe spinal muscular atrophy. Science translational 
medicine, 2011. 3(72): p. 72ra18-72ra18. 
145. Hua, Y., et al., Peripheral SMN restoration is essential for long-term rescue of a 
severe spinal muscular atrophy mouse model. Nature, 2011. 478(7367): p. 123-126. 
146. Nizzardo, M., et al., Effect of Combined Systemic and Local Morpholino Treatment on 
WKH6SLQDO0XVFXODU$WURSK\ǻ0RXVH0RGHO3KHQRW\SH Clinical therapeutics, 2014. 
36(3): p. 340-356. e5. 
147. Osman, E.Y., P.-F. Yen, and C.L. Lorson, Bifunctional RNAs targeting the intronic 
splicing silencer N1 increase SMN levels and reduce disease severity in an animal 
model of spinal muscular atrophy. Molecular Therapy, 2011. 20(1): p. 119-126. 
148. Mitrpant, C., et al., Improved antisense oligonucleotide design to suppress aberrant 
SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. 
PloS one, 2013. 8(4): p. e62114. 
149. Zou, T., et al., SMN deficiency reduces cellular ability to form stress granules, 
sensitizing cells to stress. Cellular and molecular neurobiology, 2011. 31(4): p. 
541-550. 
150. Hua, Y., et al., Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides 
targeting the exon. PLoS biology, 2007. 5(4): p. e73. 
151. Singh, N.K., et al., Splicing of a critical exon of human Survival Motor Neuron is 
regulated by a unique silencer element located in the last intron. Molecular and 
cellular biology, 2006. 26(4): p. 1333-1346. 
152. Singh, N.N., et al., A short antisense oligonucleotide masking a unique intronic motif 
prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol, 2009. 6(3): 
p. 341-350. 
153. Williams, J.H., et al., Oligonucleotide-mediated survival of motor neuron protein 
expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. 
The Journal of Neuroscience, 2009. 29(24): p. 7633-7638. 
154. Lim, S.R. and K.J. Hertel, Modulation of survival motor neuron pre-mRNA splicing 
E\ LQKLELWLRQ RI DOWHUQDWLYH ƍ VSOLFH VLWH SDLULQJ Journal of Biological Chemistry, 
2001. 276(48): p. 45476-45483. 
155. Hua, Y., et al., Motor neuron cell-nonautonomous rescue of spinal muscular atrophy 
phenotypes in mild and severe transgenic mouse models. Genes & development, 2015: 
p. gad. 256644.114. 
156. Naryshkin, N.A., et al., SMN2 splicing modifiers improve motor function and 
longevity in mice with spinal muscular atrophy. Science, 2014. 345(6197): p. 
688-693. 
157. Chang, J.-G., et al., Treatment of spinal muscular atrophy by sodium butyrate. 
Proceedings of the National Academy of Sciences, 2001. 98(17): p. 9808-9813. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
158. Brichta, L., et al., Valproic acid increases the SMN2 protein level: a well-known drug 
as a potential therapy for spinal muscular atrophy. Human molecular genetics, 2003. 
12(19): p. 2481-2489. 
159. Sumner, C.J., et al., Valproic acid increases SMN levels in spinal muscular atrophy 
patient cells. Annals of neurology, 2003. 54(5): p. 647-654. 
160. Andreassi, C., et al., Phenylbutyrate increases SMN expression in vitro: relevance for 
treatment of spinal muscular atrophy. European journal of human genetics, 2003. 
12(1): p. 59-65. 
161. Andreassi, C., et al., Aclarubicin treatment restores SMN levels to cells derived from 
type I spinal muscular atrophy patients. Human Molecular Genetics, 2001. 10(24): p. 
2841-2849. 
162. Mercuri, E., et al., Pilot trial of phenylbutyrate in spinal muscular atrophy. 
Neuromuscular Disorders, 2004. 14(2): p. 130-135. 
163. Brahe, C., et al., Phenylbutyrate increases SMN gene expression in spinal muscular 
atrophy patients. European Journal of Human Genetics, 2004. 13(2): p. 256-259. 
164. Avila, A.M., et al., Trichostatin A increases SMN expression and survival in a mouse 
model of spinal muscular atrophy. The Journal of clinical investigation, 2007. 117(117 
(3)): p. 659-671. 
165. Garbes, L., et al., LBH589 induces up to 10-fold SMN protein levels by several 
independent mechanisms and is effective even in cells from SMA patients 
non-responsive to valproate. Human molecular genetics, 2009. 18(19): p. 3645-3658. 
166. Hahnen, E., et al., Molecular analysis of candidate genes on chromosome 5q13 in 
autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of 
the SMN gene in unaffected individuals. Human molecular genetics, 1995. 4(10): p. 
1927-1933. 
167. Riessland, M., et al., SAHA ameliorates the SMA phenotype in two mouse models for 
spinal muscular atrophy. Human molecular genetics, 2010. 19(8): p. 1492-1506. 
168. Hofmann, Y., et al., Htra2-ȕVWLPXODWHVDQH[RQLFVSOLFLQJHQKDQFHUDQGFDQUHVWRUH
full-length SMN expression to survival motor neuron 2 (SMN2). Proceedings of the 
National Academy of Sciences, 2000. 97(17): p. 9618-9623. 
169. Cho, S., et al., PSF contacts exon 7 of SMN2 pre-mRNA to promote exon 7 inclusion. 
Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2014. 1839(6): 
p. 517-525. 
170. Cho, S., et al., hnRNP M facilitates exon 7 inclusion of< i>  SMN2</i> pre-mRNA in 
spinal muscular atrophy by targeting an enhancer on exon 7. Biochimica et 
Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2014. 1839(4): p. 306-315. 
171. Kashima, T., et al., hnRNP A1 functions with specificity in repression of SMN2 exon 7 
splicing. Human molecular genetics, 2007. 16(24): p. 3149-3159. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
172. Pedrotti, S., et al., The splicing regulator Sam68 binds to a novel exonic splicing 
silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. The 
EMBO journal, 2010. 29(7): p. 1235-1247. 
173. Chen, H.-H., et al., The RNA binding protein hnRNP Q modulates the utilization of 
exon 7 in the survival motor neuron 2 (SMN2) gene. Molecular and cellular biology, 
2008. 28(22): p. 6929-6938. 
174. Young, P.J., et al., SRp30c-dependent stimulation of survival motor neuron (SMN) 
H[RQLQFOXVLRQLVIDFLOLWDWHGE\DGLUHFWLQWHUDFWLRQZLWKK7UDȕ Human Molecular 
Genetics, 2002. 11(5): p. 577-587. 
175. Hofmann, Y. and B. Wirth, hnRNP-G promotes exon 7 inclusion of survival motor 
neuron (SMN) via direct interaction with Htra2-ȕ Human molecular genetics, 2002. 
11(17): p. 2037-2049. 
176. Ting, C.-H., et al., Stat5 constitutive activation rescues defects in spinal muscular 
atrophy. Human molecular genetics, 2007. 16(5): p. 499-514. 
177. Biondi, O., et al., Exercise-induced activation of NMDA receptor promotes motor unit 
development and survival in a type 2 spinal muscular atrophy model mouse. The 
Journal of Neuroscience, 2008. 28(4): p. 953-962. 
178. Andreassi, C., et al., Expression of the survival of motor neuron (SMN) gene in 
primary neurons and increase in SMN levels by activation of the 
N-methyl-D-aspartate glutamate receptor. Neurogenetics, 2002. 4(1): p. 29-36. 
179. Majumder, S., et al., Identification of a novel cyclic AMP-response element (CRE-II) 
and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron 
(SMN) gene. Journal of Biological Chemistry, 2004. 279(15): p. 14803-14811. 
180. Bassil, F., et al., Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: 
Targets for disease modification? Progress in neurobiology, 2014. 118: p. 1-18. 
181. Bosch-Marcé, M., et al., Increased IGF-1 in muscle modulates the phenotype of 
severe SMA mice. Human molecular genetics, 2011. 20(9): p. 1844-1853. 
182. Tsai, L.-K., et al., IGF-1 delivery to CNS attenuates motor neuron cell death but does 
not improve motor function in type III SMA mice. Neurobiology of disease, 2012. 
45(1): p. 272-279. 
183. Dressman, D., et al., X-linked infantile spinal muscular atrophy: clinical definition 
and molecular mapping. Genetics in Medicine, 2007. 9(1): p. 52-60. 
184. Rossor, A.M., et al., The distal hereditary motor neuropathies. Journal of Neurology, 
Neurosurgery & Psychiatry, 2012. 83(1): p. 6-14. 
185. Irobi, J., P. De Jonghe, and V. Timmerman, Molecular genetics of distal hereditary 
motor neuropathies. Human molecular genetics, 2004. 13(suppl 2): p. R195-R202. 
186. Ramser, J., et al., Rare missense and synonymous variants in UBE1 are associated 
with X-linked infantile spinal muscular atrophy. The American Journal of Human 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Genetics, 2008. 82(1): p. 188-193. 
187. Neveling, K., et al., Mutations in< i>  BICD2</i>, which Encodes a Golgin and 
Important Motor Adaptor, Cause Congenital Autosomal-Dominant Spinal Muscular 
Atrophy. The American Journal of Human Genetics, 2013. 92(6): p. 946-954. 
188. Peeters, K., et al., Molecular defects in the motor adaptor BICD2 cause proximal 
spinal muscular atrophy with autosomal-dominant inheritance. American journal of 
human genetics, 2013. 92(6): p. 955. 
189. Rossor, A.M., et al., Phenotypic and molecular insights into spinal muscular atrophy 
due to mutations in BICD2. Brain, 2015. 138(2): p. 293-310. 
190. Puls, I., et al., Mutant dynactin in motor neuron disease. Nature genetics, 2003. 33(4): 
p. 455-456. 
191. Nishimura, A.L., et al., A mutation in the vesicle-trafficking protein VAPB causes 
late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. The American 
Journal of Human Genetics, 2004. 75(5): p. 822-831. 
192. Harms, M., et al., Mutations in the tail domain of DYNC1H1 cause dominant spinal 
muscular atrophy. Neurology, 2012. 78(22): p. 1714-1720. 
193. Scoto, M., et al., Novel mutations expand the clinical spectrum of 
DYNC1H1-associated spinal muscular atrophy. Neurology, 2015: p. 10.1212/WNL. 
0000000000001269. 
194. Millecamps, S. and J.-P. Julien, Axonal transport deficits and neurodegenerative 
diseases. Nature Reviews Neuroscience, 2013. 14(3): p. 161-176. 
195. Irobi, J., et al., Hot-spot residue in small heat-shock protein 22 causes distal motor 
neuropathy. Nature genetics, 2004. 36(6): p. 597-601. 
196. Evgrafov, O.V., et al., Mutant small heat-shock protein 27 causes axonal 
Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nature genetics, 
2004. 36(6): p. 602-606. 
197. Kolb, S., et al., Mutant small heat shock protein B3 causes motor neuropathy Utility 
of a candidate gene approach. Neurology, 2010. 74(6): p. 502-506. 
198. Dubowitz, V., Muscle disorders in childhood. Major Probl Clin Pediatr, 1978. 16: p. 
iii-xiii, 1-282. 
199. Kariya, S., et al., Reduced SMN protein impairs maturation of the neuromuscular 
junctions in mouse models of spinal muscular atrophy. Human molecular genetics, 
2008. 17(16): p. 2552-2569. 
200. Murray, L.M., et al., Selective vulnerability of motor neurons and dissociation of 
pre-and post-synaptic pathology at the neuromuscular junction in mouse models of 
spinal muscular atrophy. Human molecular genetics, 2008. 17(7): p. 949-962. 
201. Iwata, M. and A. Hirano, Sparing of the Onufrowicz nucleus in sacral anterior horn 
lesions. Annals of neurology, 1978. 4(3): p. 245-249. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
202. Sung, J.H. and A.R. Mastri, Spinal autonomic neurons in Werdnig-Hoffmann disease, 
mannosidosis, and Hurler's syndrome: distribution of autonomic neurons in the sacral 
spinal cord. Journal of Neuropathology & Experimental Neurology, 1980. 39(4): p. 
441-451. 
203. Kubota, M., et al., New ocular movement detector system as a communication tool in 
ventilatorͲassisted WerdnigͲHoffmann disease. Developmental Medicine & Child 
Neurology, 2000. 42(1): p. 61-64. 
204. Thomson, S.R., et al., Morphological characteristics of motor neurons do not 
determine their relative susceptibility to degeneration in a mouse model of severe 
spinal muscular atrophy. PloS one, 2012. 7(12): p. e52605. 
205. Ling, K.K., et al., Severe neuromuscular denervation of clinically relevant muscles in 
a mouse model of spinal muscular atrophy. Human molecular genetics, 2012. 21(1): p. 
185-195. 
206. Brockington, A., et al., Unravelling the enigma of selective vulnerability in 
neurodegeneration: motor neurons resistant to degeneration in ALS show distinct 
gene expression characteristics and decreased susceptibility to excitotoxicity. Acta 
neuropathologica, 2013. 125(1): p. 95-109. 
207. Hedlund, E., et al., Global gene expression profiling of somatic motor neuron 
populations with different vulnerability identify molecules and pathways of 
degeneration and protection. Brain, 2010. 133(8): p. 2313-2330. 
208. Murray, L.M., et al., Transcriptional profiling of differentially vulnerable motor 
neurons at pre-symptomatic stage in the Smn 2b/-mouse model of spinal muscular 
atrophy. Acta neuropathologica communications, 2015. 3(1): p. 1. 
209. Fallini, C., G.J. Bassell, and W. Rossoll, The ALS disease protein TDP-43 is actively 
transported in motor neuron axons and regulates axon outgrowth. Human molecular 
genetics, 2012. 21(16): p. 3703-3718. 
210. Yamazaki, T., et al., FUS-SMN protein interactions link the motor neuron diseases 
ALS and SMA. Cell reports, 2012. 2(4): p. 799-806. 
211. Kariya, S., et al., Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic 
lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein 
to nuclear Cajal bodies. Human molecular genetics, 2012: p. dds174. 
212. Turner, B.J., et al., Survival motor neuron deficiency enhances progression in an 
amyotrophic lateral sclerosis mouse model. Neurobiology of disease, 2009. 34(3): p. 
511-517. 
 
 
. 
ACCEPTED MANUSCRIPT
